April Bio (KRX: 397030)
Who is buying April Bio?
Between Sep 15, 2026 and Oct 16, 2026 (20 trading sessions), foreign investors net sold ₩9.1bn ($7M) of April Bio, the 54th largest foreign net sale among 1828 KOSDAQ stocks. Institutions net sold ₩2.5bn ($2M) and retail investors net bought ₩11.7bn ($9M) over the same window. Foreigners were net buyers on 10 of the 20 sessions.
Foreign investors hold 8.78% of April Bio's listed shares (KRX ownership data as of Oct 16, 2026), down from 9.89% twenty sessions earlier and 2.81% a year ago.
The stock closed at ₩12,840 on Oct 16, 2026: -23.80% over 20 sessions, -76.61% year-to-date, -58.91% over one year. The 52-week range is ₩11,810 – ₩76,700.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-16 | ₩12,840 | +₩1.5bn | ₩-0.5bn | ₩-0.9bn |
| 2026-10-15 | ₩12,030 | +₩0.8bn | ₩-0.0bn | ₩-0.7bn |
| 2026-10-14 | ₩12,910 | +₩0.2bn | +₩0.0bn | ₩-0.2bn |
| 2026-10-13 | ₩12,890 | +₩0.9bn | +₩0.0bn | ₩-0.9bn |
| 2026-10-12 | ₩13,410 | +₩1.4bn | ₩-0.2bn | ₩-1.2bn |
| 2026-10-08 | ₩14,560 | +₩0.8bn | ₩-1.0bn | +₩0.2bn |
| 2026-10-07 | ₩15,750 | ₩-0.1bn | +₩0.1bn | ₩-0.0bn |
| 2026-10-06 | ₩16,030 | +₩0.8bn | ₩-2.6bn | +₩2.3bn |
| 2026-10-02 | ₩17,020 | ₩-12.5bn | ₩-5.8bn | +₩18.2bn |
| 2026-10-01 | ₩21,300 | ₩-0.3bn | +₩0.5bn | ₩-0.2bn |
| 2026-09-30 | ₩20,200 | +₩1.0bn | +₩1.7bn | ₩-2.7bn |
| 2026-09-29 | ₩18,690 | ₩-1.3bn | +₩0.7bn | +₩0.5bn |
| 2026-09-28 | ₩18,700 | ₩-0.2bn | +₩1.0bn | ₩-1.0bn |
| 2026-09-23 | ₩18,110 | +₩0.2bn | +₩0.1bn | ₩-0.3bn |
| 2026-09-22 | ₩17,800 | ₩-0.6bn | ₩-0.1bn | +₩0.8bn |
| 2026-09-21 | ₩18,400 | +₩0.0bn | +₩0.8bn | ₩-0.9bn |
| 2026-09-18 | ₩18,280 | ₩-0.9bn | +₩1.2bn | ₩-0.3bn |
| 2026-09-17 | ₩18,040 | ₩-0.4bn | +₩0.5bn | ₩-0.2bn |
| 2026-09-16 | ₩17,680 | ₩-0.4bn | +₩0.7bn | ₩-0.3bn |
| 2026-09-15 | ₩17,180 | ₩-0.1bn | +₩0.6bn | ₩-0.5bn |
| 2026-09-14 | ₩16,850 | ₩-0.7bn | +₩0.6bn | +₩0.0bn |
| 2026-09-11 | ₩17,130 | ₩-0.5bn | +₩0.5bn | +₩0.0bn |
| 2026-09-10 | ₩17,250 | ₩-0.6bn | +₩0.0bn | +₩0.4bn |
| 2026-09-09 | ₩17,520 | ₩-0.2bn | +₩0.0bn | +₩0.2bn |
| 2026-09-08 | ₩17,570 | ₩-0.4bn | ₩-0.0bn | +₩0.8bn |
| 2026-09-07 | ₩18,180 | ₩-0.4bn | +₩0.3bn | ₩-0.0bn |
| 2026-09-04 | ₩17,800 | +₩0.3bn | +₩0.0bn | ₩-0.3bn |
| 2026-09-03 | ₩16,770 | +₩0.6bn | +₩0.0bn | ₩-0.6bn |
| 2026-09-02 | ₩17,120 | ₩-0.6bn | ₩-0.0bn | +₩0.6bn |
| 2026-09-01 | ₩18,020 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-31 | ₩17,910 | +₩1.7bn | ₩-0.7bn | ₩-1.0bn |
| 2026-08-28 | ₩18,550 | ₩-2.4bn | ₩-0.1bn | +₩2.5bn |
| 2026-08-27 | ₩19,270 | +₩0.1bn | ₩-0.7bn | +₩0.4bn |
| 2026-08-26 | ₩19,190 | +₩0.7bn | ₩-1.7bn | +₩0.9bn |
| 2026-08-25 | ₩19,470 | +₩0.4bn | ₩-0.1bn | ₩-0.4bn |
| 2026-08-24 | ₩19,940 | +₩0.5bn | +₩0.1bn | ₩-0.6bn |
| 2026-08-21 | ₩19,840 | +₩0.2bn | ₩-1.6bn | +₩1.4bn |
| 2026-08-20 | ₩21,250 | ₩-0.4bn | ₩-6.2bn | +₩6.5bn |
| 2026-08-19 | ₩26,300 | +₩0.8bn | ₩-2.0bn | +₩1.1bn |
| 2026-08-18 | ₩26,350 | +₩1.4bn | ₩-1.1bn | ₩-0.4bn |
| 2026-08-14 | ₩28,300 | ₩-0.6bn | ₩-0.5bn | +₩1.1bn |
| 2026-08-13 | ₩29,150 | ₩-0.0bn | ₩-0.2bn | +₩0.2bn |
| 2026-08-12 | ₩28,500 | ₩-0.3bn | ₩-0.4bn | +₩0.7bn |
| 2026-08-11 | ₩29,900 | ₩-1.3bn | +₩1.2bn | +₩0.1bn |
| 2026-08-10 | ₩30,650 | ₩-2.0bn | +₩3.1bn | ₩-1.0bn |
| 2026-08-07 | ₩27,600 | ₩-0.3bn | +₩0.2bn | +₩0.1bn |
| 2026-08-06 | ₩28,400 | ₩-7.4bn | +₩4.0bn | +₩3.4bn |
| 2026-08-05 | ₩26,550 | ₩-0.3bn | ₩-0.0bn | +₩0.3bn |
| 2026-08-04 | ₩25,400 | +₩3.5bn | +₩0.9bn | ₩-4.3bn |
| 2026-08-03 | ₩23,900 | ₩-0.4bn | +₩0.1bn | +₩0.3bn |
| 2026-07-31 | ₩22,150 | +₩0.5bn | +₩0.3bn | ₩-0.8bn |
| 2026-07-30 | ₩19,490 | +₩0.2bn | ₩-0.0bn | ₩-0.2bn |
| 2026-07-29 | ₩20,700 | +₩2.2bn | +₩0.3bn | ₩-2.5bn |
| 2026-07-28 | ₩22,850 | +₩0.4bn | +₩0.1bn | ₩-0.4bn |
| 2026-07-27 | ₩25,050 | ₩-0.1bn | +₩0.2bn | ₩-0.1bn |
| 2026-07-24 | ₩24,800 | ₩-1.0bn | +₩0.1bn | +₩0.9bn |
| 2026-07-23 | ₩26,550 | ₩-0.9bn | ₩-0.5bn | +₩1.4bn |
| 2026-07-22 | ₩24,500 | +₩0.5bn | ₩-0.2bn | ₩-0.2bn |
| 2026-07-21 | ₩23,500 | +₩0.3bn | ₩-1.1bn | +₩0.8bn |
| 2026-07-20 | ₩24,000 | +₩1.1bn | ₩-0.2bn | ₩-0.8bn |
| 2026-07-16 | ₩25,200 | ₩-0.9bn | +₩0.1bn | +₩0.7bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩1.5bn | +$1M | ₩-0.5bn | ₩-0.9bn |
| 5 days | +₩4.7bn | +$3M | ₩-0.7bn | ₩-4.0bn |
| 20 days | ₩-9.1bn | $-7M | ₩-2.5bn | +₩11.7bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying April Bio stock?
Over the last 5 sessions foreign investors net bought ₩4.7bn ($3M) of April Bio; over 60 sessions they net sold ₩14.6bn ($11M); since Jan 1, 2026 they net bought ₩91.6bn ($68M). Over 20 sessions the stock is the 54th largest foreign net sale among 1828 KOSDAQ stocks.
How much of April Bio do foreign investors own?
Foreign investors own 8.78% of April Bio's shares as of Oct 16, 2026, versus 2.81% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩2.5bn ($2M) and retail investors net bought ₩11.7bn ($9M) of April Bio. Retail investors have been absorbing what foreigners and institutions are selling.
Is April Bio listed on KOSPI or KOSDAQ?
April Bio (에이프릴바이오) trades on KOSDAQ under KRX code 397030 in the Biotech & Pharma group, with a market capitalization of ₩0T ($0.3B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | – | – | -₩13bn (-$10M) | -₩14bn (-$10M) |
| 2024 | – | – | ₩17bn ($13M) | ₩20bn ($15M) |
| 2025 | – | – | -₩7bn (-$5M) | -₩10bn (-$7M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1345.9/$) for reference only.